Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
80.39
-2.71 (-3.26%)
Oct 23, 2026, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Mirum Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $153.43. The average 1-year stock price forecast is 90.86% higher than the current stock price, while the lowest is $118 (+46.78%) and the highest is $200 (+148.79%).
Price Target: $153.43 (+90.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Mirum Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 10 | 10 | 10 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $140 → $195 | Buy | Maintains | $140 → $195 | +142.57% | Oct 22, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $140 → $145 | Buy | Maintains | $140 → $145 | +80.37% | Oct 21, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $136 → $156 | Buy | Maintains | $136 → $156 | +94.05% | Oct 14, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 13, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $135 → $146 | Buy | Maintains | $135 → $146 | +81.61% | Oct 13, 2026 |
Financial Forecast
Revenue This Year
698.11M
from 521.31M
Increased by 33.91%
Revenue Next Year
819.59M
from 698.11M
Increased by 17.40%
EPS This Year
-15.23
from -0.47
EPS Next Year
-0.71
from -15.23
EPS and Forward PE are based on non-GAAP adjusted numbers.